#最小單位貼紙

抗病毒藥品 Treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease

Nucleotide Reverse Transcriptase Inhibitor (Anti-HBV)
Tenofovir alafenamide, an analog of adenosine 5'-monophosphate, is converted intracellularly by hydrolysis to tenofovir and subsequently phosphorylated to the active tenofovir diphosphate. The active moiety inhibits replication of HBV by inhibiting HBV polymerase.

1. Protein binding: 80% to plasma proteins.
2. Metabolism: Tenofovir alafenamide (TAF) is converted intracellularly to tenofovir, then phosphorylated to the active tenofovir diphosphate.
3. Bioavailability: Increases ~65% with a high-fat meal
4. Half-life elimination: 0.51 hours
5. Time to peak, serum: 0.48 hours
6. Excretion: Feces (31.7%) and urine (<1%)

Hypersensitivity to tenofovir alafenamide or any component of the formulation

Females coinfected with HIV and HBV who are taking tenofovir alafenamide prior to pregnancy should be offered a choice to switch to tenofovir disoproxil fumarate or continue with the current regimen.

Breastfeeding is not contraindicated in women with hepatitis B; however, if nipples are cracked or bleeding, breastfeeding is not recommended.

Headache, Decreased bone mineral density

25 mg once daily

1. CrCl ≥15 mL/minute: No dosage adjustment necessary
2. CrCl <15 mL/minute: Use is not recommended

1. Mild impairment (Child-Pugh class A): No dosage adjustment necessary
2. Decompensated cirrhosis (Child-Pugh class B or C): Use is not recommended